Latest News and Press Releases

FLORHAM PARK, N.J., Oct. 04, 2022 (GLOBE NEWSWIRE) -- Real Endpoints, the leading market-access platform and advisory firm, announced a collaboration with bluebird bio, inc. (Nasdaq: BLUE), to...

FLORHAM PARK, N.J., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Citing his creativity, entrepreneurialism, and leadership over the last 30 years, PharmaVOICE magazine has named Roger Longman, chairman of Real...

The RE Marketplace established with four founding health plans representing nearly 2.5 million lives. Each plan and its beneficiaries get immediate access to contracts for all biotech drugs in the...

FLORHAM PARK, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a leading boutique life science consultancy focused on market access, today announced it has hired Robert O’Brien as Vice...

MADISON, N.J., Aug. 06, 2019 (GLOBE NEWSWIRE) -- Real Endpoints (RE), an advisory and analytics firm entirely focused on enhancing appropriate access to healthcare innovation, announced today that...

MADISON, N.J., Sept. 13, 2018 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a leader in the development and implementation of proprietary tools to strengthen pharmaceutical market access for an evolving...

SAN DIEGO, WELLESLEY, Mass. and WESTPORT, Conn., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Illumina, Inc. and Harvard Pilgrim Health Care announced on February 1 a major new value-based contract (VBC) – one...

WESTPORT, Conn., July 17, 2017 (GLOBE NEWSWIRE) -- Real Endpoints (RE), a data, analytics, and advisory company that helps payers and biopharma companies define the value and economic impact of new...

WESTPORT, CT--(Marketwired - January 31, 2017) - Real Endpoints, LLC (RE), a data and analytics firm focusing on assessing and quantifying pharmaceutical value, has just completed an extensive...

WESTPORT, CT--(Marketwired - Oct 13, 2014) - Gilead's Harvoni (sofosbuvir/ledipasvir combination) is the top overall scorer, according to RxScorecard, a drug-value assessment tool from Real...